ESTRO 2024 - Abstract Book

S4649

Physics - Optimisation, algorithms and applications for ion beam treatment planning

ESTR0 2024

Fig. 2. Top: Reconstructed 2D PET images in the coronal plane of the activated volume of the head phantom: A) experimental; B) simulation. Bottom: 1D projection profiles from the reconstructed 2D images of the head phantom. C) longitudinal in the beam direction (negative Y direction); D) lateral.

Conclusion:

Our Monte Carlo framework based on RayStation/GATE to support the in-beam PET method for quality assurance of proton therapy, including the very short-lived isotope 12N, was validated against experiments with an anthropomorphic head phantom. This result represents a significant step towards translating 12N real-time in vivo verification to the clinic.

Keywords: Proton therapy, N-12 imaging, RayStation

References:

[1] Knopf A-C and Lomax A 2013 In vivo proton range verification: a review Phys. Med. Biol 58R131.

[2] Buitenhuis HJT, Diblen F, Brzezinski KW, Brandenburg S and Dendooven P 2017 Beam-on imaging of short-lived positron emitters during proton therapy Phys. Med. Biol. 62 4654–4672.

[3] Dendooven P, Buitenhuis HJT, Diblen F, Heeres PN, Biegun AK, Fiedler F, van Goethem MJ, van der Graaf ER and Brandenburg, S 2015 Short-lived positron emitters in beam-on PET imaging during proton therapy Phys. Med. Biol. 60 8923–8947.

1708

Digital Poster

Automated proton IMPT treatment planning for plan comparison for breast cancer

Anne Lisa Wolf 1 , Jenneke Jacobs 1 , Yibing Wang 1 , Diede Wijnbergen 1 , Albert Licup 1 , Mariana Piedade 1 , Angelo Malefijt 1 , Sophie Bosma 1,2 , Mischa Hoogeman 1,3 1 HollandPTC, Holland Proton Therapy Center, Delft, Netherlands. 2 The Netherlands Cancer Institute, Department of Radiotherapy, Amsterdam, Netherlands. 3 Erasmus MC Cancer Institute, Department of Radiotherapy, Rotterdam, Netherlands

Purpose/Objective:

In the Netherlands, proton therapy is reimbursed for standard indications if the reduced dose to the organs at risk is predicted to translate in clinically significant less toxicity based on Normal Tissue Complication Probability (NTCP) models (the model-based approach). Patients treated for breast cancer are a.o. eligible for proton therapy in case the